Dr. Chunyan Lan 蓝春燕
Chief Physician
Department of Gynecology, Sun Yat-sen University Cancer Center, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radical and fertility-sparing surgery for cervical, ovarian, and endometrial cancers. Complex surgeries for recurrent cases. Comprehensive treatment including targeted and immunotherapy for recurrent gynecologic malignancies.
Dr. Lan is a Chief Physician and MD/PhD from Sun Yat-sen University. Dr. Lan performs open and minimally invasive surgeries, including QM-C type radical hysterectomy and cytoreductive surgery. Research focuses on recurrent drug-resistant gynecologic tumors, with findings published in Lancet Oncology and Journal of Clinical Oncology. Dr. Lan holds grants from the National Natural Science Foundation of China and was named an Outstanding Young Medical Talent in Guangdong Province.
Professional roles
- Standing Committee Member, Integrated Traditional Chinese and Western Medicine Ovarian Cancer Professional Committee, China Anti-Cancer Association
- Vice Chair, Obstetrics and Gynecology Branch, Guangdong Health Economics Association
- Standing Committee Member, First Committee of Gynecologic Oncology Multidisciplinary Collaboration Professional Committee, Guangdong Health Management Association
- Standing Committee Member, First Gynecologic Oncology Expert Committee, Guangdong Pharmaceutical Association
Name order: in Chinese the family name comes first (Lan Chunyan). Papers usually list the name as Chunyan Lan or Lan C.
Selected publications
23 papers on PubMed matched by name and affiliation; 9 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Pharm Biomed Anal, 2026 (senior author): Corrigendum to "Development and validation of a sensitive LC-MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients" [J. Pharmaceut. Biomed. Anal. 237 (2024) 115758]. PubMed 42987689
- Nat Commun, 2026 (senior author): Cadonilimab plus lenvatinib in advanced endometrial cancer: the multicenter single-arm phase II CLEAR-EC trial. PubMed 42838953
- BMC Med, 2026 (senior author): Pamiparib plus surufatinib with ctDNA monitoring in platinum-resistant ovarian cancer after PARP inhibitor progression: a phase Ib/II trial (POST-PARPi). PubMed 43021280
- J Gynecol Oncol, 2026 (senior author): Adiposity enhances the anti-metastatic efficacy of apatinib via PKA-mediated lipid metabolism. PubMed 42317124
- Cancer Discov, 2026 (first author): Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer. PubMed 41511850
- J Pharm Biomed Anal, 2024 (senior author): Development and validation of a sensitive LC-MS/MS method for the assay of four PARP inhibitors in human plasma and its application in ovarian cancer patients. PubMed 37832476
- EClinicalMedicine, 2023 (senior author): Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: a multicenter, open-label, single-arm, phase II trial. PubMed 38106561
- J Immunother Cancer, 2021 (senior author): Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial. PubMed 34011535
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion